- Home
- INMB vs KPTI Comparison
INMB vs KPTI Comparison
Compare INMB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- KPTI
- Stock Information
- Founded
- INMB 2015
- KPTI 2008
- Country
- INMB United States
- KPTI United States
- Employees
- INMB N/A
- KPTI N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- KPTI Health Care
- Exchange
- INMB Nasdaq
- KPTI Nasdaq
- Market Cap
- INMB 103.1M
- KPTI 90.7M
- IPO Year
- INMB 2019
- KPTI 2013
- Fundamental
- Price
- INMB $6.53
- KPTI $0.69
- Analyst Decision
- INMB Strong Buy
- KPTI Strong Buy
- Analyst Count
- INMB 2
- KPTI 4
- Target Price
- INMB $21.00
- KPTI $5.00
- AVG Volume (30 Days)
- INMB 369.6K
- KPTI 1.0M
- Earning Date
- INMB 10-31-2024
- KPTI 02-27-2025
- Dividend Yield
- INMB N/A
- KPTI N/A
- EPS Growth
- INMB N/A
- KPTI N/A
- EPS
- INMB N/A
- KPTI N/A
- Revenue
- INMB $42,000.00
- KPTI $148,442,000.00
- Revenue This Year
- INMB N/A
- KPTI $5.47
- Revenue Next Year
- INMB N/A
- KPTI $6.33
- P/E Ratio
- INMB N/A
- KPTI N/A
- Revenue Growth
- INMB N/A
- KPTI 1.77
- 52 Week Low
- INMB $4.32
- KPTI $0.58
- 52 Week High
- INMB $14.74
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- INMB 64.22
- KPTI 47.36
- Support Level
- INMB $6.04
- KPTI $0.61
- Resistance Level
- INMB $6.83
- KPTI $0.73
- Average True Range (ATR)
- INMB 0.56
- KPTI 0.07
- MACD
- INMB 0.17
- KPTI -0.00
- Stochastic Oscillator
- INMB 86.76
- KPTI 34.06
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.